{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:41:58Z","timestamp":1767339718887,"version":"3.48.0"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2021-0074_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Vitamin D is an important regulator of the immune system, and it has been shown that deficiency of vitamin D is significant environmental factor in some immune-mediated diseases such as Multiple Sclerosis (MS). In this study, we have compared serum 25 hydroxyvitamin (OH) D levels in Relapsing-Remitting Multiple Sclerosis (RRMS), clinically isolated syndrome (CIS), and control groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0074_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty patients with CIS and 60 patients who have been diagnosed RRMS between age 18\u201345, respectively, and followed up at Pamukkale University Faculty of Medicine, Department of Neurology, and 60 healthy individuals have been included in this study. Serum 25(OH) vitamin D, calcium, phosphorus, alkaline phosphatase, parathormone, insulin, and fasting blood glucose levels were studied for all three groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0074_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A statistically significant difference was determined in the comparison of three groups for mean 25(OH) vitamin D levels. In the intergroup comparison of mean 25(OH) vitamin D; mean 25(OH) vitamin D level was determined to be statistically significantly lower in both\u00a0RRMS and CIS groups compared to control group (p&lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0074_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Since vitamin D deficiency poses a problem from the early stage of disease spectrum in both CIS patients and MS patients, 25(OH) vitamin D level should be routinely controlled, and replacement should be administered upon any deficiency state.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2021-0074","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T05:01:40Z","timestamp":1649653300000},"page":"281-288","source":"Crossref","is-referenced-by-count":3,"title":["Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups"],"prefix":"10.1515","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1547-341X","authenticated-orcid":false,"given":"Ahmet","family":"K\u00fc\u00e7\u00fck","sequence":"first","affiliation":[{"name":"Department of Neurology , Faculty of Medicine, Pamukkale University , Denizli , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-3756","authenticated-orcid":false,"given":"Levent Sinan","family":"Bir","sequence":"additional","affiliation":[{"name":"Department of Neurology , Faculty of Medicine, Pamukkale University , Denizli , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-0510","authenticated-orcid":false,"given":"Selma","family":"Tekin","sequence":"additional","affiliation":[{"name":"Department of Neurology , Faculty of Medicine, Pamukkale University , Denizli , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-4040","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry , Faculty of Medicine, Pamukkale University , Denizli , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"2025121207225431420_j_hmbci-2021-0074_ref_001","doi-asserted-by":"crossref","unstructured":"Munger, K, Levin, L, Hollis, B, Howard, N, Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832. https:\/\/doi.org\/10.1001\/jama.296.23.2832.","DOI":"10.1001\/jama.296.23.2832"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_002","doi-asserted-by":"crossref","unstructured":"Munger, K, Ascherio, A. Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler J 2011;17:1405\u201311. https:\/\/doi.org\/10.1177\/1352458511425366.","DOI":"10.1177\/1352458511425366"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_003","doi-asserted-by":"crossref","unstructured":"Smolders, J, Torkildsen, \u00d8, Camu, W, H\u00f8lmoy, T. An update on vitamin D and disease activity in multiple sclerosis. CNS Drugs 2019;33:1187\u201399. https:\/\/doi.org\/10.1007\/s40263-019-00674-8.","DOI":"10.1007\/s40263-019-00674-8"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_004","doi-asserted-by":"crossref","unstructured":"Lucas, R, Ponsonby, A, Dear, K, Valery, P, Pender, M, Taylor, B, et al.. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011;76:540\u20138. https:\/\/doi.org\/10.1212\/wnl.0b013e31820af93d.","DOI":"10.1212\/WNL.0b013e31820af93d"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_005","doi-asserted-by":"crossref","unstructured":"Holick, MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73\u20138. https:\/\/doi.org\/10.1016\/j.annepidem.2007.12.001.","DOI":"10.1016\/j.annepidem.2007.12.001"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_006","unstructured":"G\u00f6k\u00e7en Tolgay, EN. Evaluation of serum vitamin D levels and its relation with neuropsychological tests during relapse and remission periods in relapsing remitting multiple sclerosis patients. Bursa, Turkey: Uludag University; 2011."},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_007","unstructured":"Candan, F\u00dc. Evaluation of 25 hydroxycalciferol levels in multiple sclerosis patients with cranial magnetic resonance images. Istanbul: Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatric and Neurological Diseases; 2013."},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_008","doi-asserted-by":"crossref","unstructured":"Mowry, E, Krupp, L, Milazzo, M, Chabas, D, Strober, J, Belman, A, et al.. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010;67:618\u201324. https:\/\/doi.org\/10.1002\/ana.21972.","DOI":"10.1002\/ana.21972"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_009","doi-asserted-by":"crossref","unstructured":"Martinelli, V, Costa, G, Colombo, B, Libera, D, Rubinacci, A, Filippi, M, et al.. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler J 2014;20:147\u201355. https:\/\/doi.org\/10.1177\/1352458513494959.","DOI":"10.1177\/1352458513494959"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_010","doi-asserted-by":"crossref","unstructured":"Smolders, J, Menheere, P, Kessels, A, Damoiseaux, J, Hupperts, R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220\u20134. https:\/\/doi.org\/10.1177\/1352458508094399.","DOI":"10.1177\/1352458508094399"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_011","doi-asserted-by":"crossref","unstructured":"Van Der Mei, IAF, Ponsonby, AL, Dwyer, T, Blizzard, L, Taylor, BV, Kilpatrick, T, et al.. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581\u201390. https:\/\/doi.org\/10.1007\/s00415-006-0315-8.","DOI":"10.1007\/s00415-006-0315-8"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_012","doi-asserted-by":"crossref","unstructured":"Runia, TF, Hop, WCH, Rijke, YB, Buljevac, D, Hintzen, RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261\u20136. https:\/\/doi.org\/10.1212\/wnl.0b013e31825fdec7.","DOI":"10.1212\/WNL.0b013e31825fdec7"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_013","doi-asserted-by":"crossref","unstructured":"Simpson, S, Taylor, B, Blizzard, L, Ponsonby, AL, Pittas, F, Tremlett, H, et al.. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193\u2013203. https:\/\/doi.org\/10.1002\/ana.22043.","DOI":"10.1002\/ana.22043"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_014","doi-asserted-by":"crossref","unstructured":"Earl, F, Umed, A, McGuire Lisa, LS. Concentrations of serum vitamin D and. Diabetes Care 2005;28:1228\u201330.","DOI":"10.2337\/diacare.28.5.1228"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_015","doi-asserted-by":"crossref","unstructured":"Ford, ES, Zhao, G, Tsai, J, Li, C. Associations between concentrations of vitamin D and concentrations of insulin, glucose, and HbA 1camong adolescents in the United States. Diabetes Care 2011;34:646\u20138. https:\/\/doi.org\/10.2337\/dc10-1754.","DOI":"10.2337\/dc10-1754"},{"key":"2025121207225431420_j_hmbci-2021-0074_ref_016","doi-asserted-by":"crossref","unstructured":"Auer, DP, Schumann, EM, K\u00fcmpfel, T, G\u00f6ssl, C, Trenkwalder, C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276\u20137. https:\/\/doi.org\/10.1002\/1531-8249(200002)47:2<276::aid-ana28>3.0.co;2-1.","DOI":"10.1002\/1531-8249(200002)47:2<276::AID-ANA28>3.3.CO;2-T"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0074\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:18:25Z","timestamp":1765527505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0074\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2022,9,28]]}},"alternative-id":["10.1515\/hmbci-2021-0074"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2021-0074","relation":{},"ISSN":["1868-1891"],"issn-type":[{"type":"electronic","value":"1868-1891"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}